1150 related articles for article (PubMed ID: 11599633)
1. Specific immunotherapy of cancer in elderly patients.
Matzku S; Zöller M
Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
4. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
5. Peptide-based vaccines for cancer immunotherapy.
Brinkman JA; Fausch SC; Weber JS; Kast WM
Expert Opin Biol Ther; 2004 Feb; 4(2):181-98. PubMed ID: 14998777
[TBL] [Abstract][Full Text] [Related]
6. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
Jäger D; Jäger E; Knuth A
J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
[TBL] [Abstract][Full Text] [Related]
8. Innovative cancer vaccine strategies based on the identification of tumour-associated antigens.
Ying H; Zeng G; Black KL
BioDrugs; 2001; 15(12):819-31. PubMed ID: 11784213
[TBL] [Abstract][Full Text] [Related]
9. [Immune alterations in lung cancer - the new therapeutic approach].
Domagała-Kulawik J; Osińska I
Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
11. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
12. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
13. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?
Zöller M
Technol Cancer Res Treat; 2003 Jun; 2(3):237-60. PubMed ID: 12779354
[TBL] [Abstract][Full Text] [Related]
15. Immunologic mechanisms of antitumor activity.
Foss FM
Semin Oncol; 2002 Jun; 29(3 Suppl 7):5-11. PubMed ID: 12068382
[TBL] [Abstract][Full Text] [Related]
16. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
[TBL] [Abstract][Full Text] [Related]
17. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy II: Antigens, receptors and costimulation.
Searle PF; Young LS
Cancer Metastasis Rev; 1996 Sep; 15(3):329-49. PubMed ID: 9034595
[TBL] [Abstract][Full Text] [Related]
20. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
